Amgen Posts 10% Revenue Growth Amid Patent Losses
Amgen delivered 10% year-over-year revenue growth in Q2 despite losing patent exclusivity for a product that previously contributed nearly 20% of its total sales.
Amgen reported second-quarter total revenue of $10.1 billion, marking a 10% increase over the same period last year. This financial performance was achieved while the company managed the expiration of patent exclusivity for denosumab, a key asset sold under the brands Prolia and Xgeva. In 2024, this single medicine accounted for nearly 20% of Amgen's total revenue, making the company's ability to sustain growth without it a critical operational test.
The drugmaker’s resilience is evident in its historical performance during market downturns. According to data reviewed by GN stocks/sp500, Amgen shares gained value in 2008 and 2022, periods when the S&P 500 experienced significant declines. This trajectory contrasts with the broader market's volatility, suggesting that the company’s revenue streams provide a buffer against macroeconomic shocks such as inflation and rising interest rates.
Portfolio Diversification Offsets Patent Cliffs
Amgen’s revenue growth was driven by a broad-based improvement across its product lines. Twenty-two of the company’s medicines posted double-digit sales growth in the recent quarter. This distribution of earnings allows the business to absorb the financial impact of patent cliffs, such as the recent loss of exclusivity for denosumab in the U.S. and Europe, without a corresponding drop in total top-line results.
Pipeline Progress And Clinical Setbacks
The company is advancing MariTide, a long-acting weight-loss candidate for obesity and related conditions, in a rapidly expanding market segment. However, investors reacted to a clinical failure by Novartis, whose drug Pelacarsen failed to reduce cardiovascular risk in patients with elevated lipoprotein(a). This event caused Amgen shares to fall approximately 10% in a single day, reflecting concerns about its own candidate, olpasiran, which targets the same biomarker.
Despite the competitive setback from Novartis, Amgen’s phase 3 studies for olpasiran are still ongoing. The company maintains a deep pipeline that includes multiple attractive candidates, meaning a single clinical issue does not compromise the overall strategic outlook. This depth provides a layer of security for long-term revenue projections independent of any single drug's success.
Dividend Yield Exceeds Market Average
Amgen continues to increase its dividend payout annually, a practice maintained since 2011. The current dividend yield stands at 2.6%, significantly higher than the 1.1% average for the S&P 500. This cash flow component offers a return mechanism for shareholders that is distinct from stock price appreciation, providing a financial cushion during periods of equity market volatility.
